Physician profile
Anthony Luistro
NPI 1396922076
$10,434.90
in general payments reported to CMS, 2019-2025
37 companies · $1,765 in 2025
The $1,765 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,014 · 2020: $704 · 2021: $1,120 · 2022: $762 · 2023: $1,287 · 2024: $1,782 · 2025: $1,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,834.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,371.12 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,306.41 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,115.15 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Novo Nordisk INC | $1,100.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,065.32 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $656.43 | 2019-2023 | |
| Exact Sciences Corporation | $534.27 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $396.61 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $332.01 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Astellas Pharma US INC | $329.93 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $278.83 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $270.98 | 2023-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $227.42 | 2023-2025 | |
| Abbott Laboratories | $206.78 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $155.61 | 2021-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $154.97 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $131.08 | 2019-2021 | |
| Medtronic Minimed, INC. | $130.74 | 2019-2020 | |
| Daiichi Sankyo INC. | $92.06 | 2021-2022 | |
| Optinose US, INC. | $82.89 | 2025 | |
| Becton, Dickinson and Company | $61.35 | 2019 | |
| Circassia INC. | $57.56 | 2019-2020 | |
| Dexcom, INC. | $54.87 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $51.37 | 2025 | Otezla, Repatha |
| Hikma Pharmaceuticals USA | $43.18 | 2019-2022 | |
| Sanofi Pasteur INC. | $40.99 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $28.86 | 2024-2025 | Gemtesa |
| Dynavax Technologies Corporation | $19.50 | 2021 | |
| Hologic Sales and Service, LLC | $18.82 | 2024 | Aptima |
| Bavarian Nordic A/S | $18.12 | 2025 | Vivotif |
| Smith+Nephew, INC. | $17.87 | 2019 | |
| Akebia Therapeutics INC | $15.84 | 2019 | |
| Mannkind Corporation | $15.38 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.80 | 2025 | Zoryve |
| Phadia US INC. | $12.98 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Luistro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.